Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-10

Clinical Trial Update: Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy [Phase 3]

View source ↗

Summary

Phase 3 trial update presenting long-term outcomes for ataluren in Duchenne muscular dystrophy; results were posted in March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Translarna (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies | Phase 3 | Status: COMPLETED | Results posted: 2026-03-10